{"id":"cytarabine-and-mitoxantrone","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Myelosuppression"},{"rate":"20-40%","effect":"Nausea and vomiting"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Infection"},{"rate":"5-15%","effect":"Cardiac toxicity"}]},"_chembl":null,"_fixedAt":"2026-03-30T17:05:41.113408","_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Cytarabine works by incorporating itself into DNA, causing strand breaks and inhibiting DNA synthesis. Mitoxantrone, on the other hand, intercalates DNA and inhibits topoisomerase II, leading to DNA damage and apoptosis. This combination of mechanisms makes cytarabine and mitoxantrone effective against rapidly dividing cancer cells.","oneSentence":"Cytarabine is a nucleoside analog that interferes with DNA synthesis, while mitoxantrone is a topoisomerase II inhibitor that disrupts DNA replication and transcription.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:08:22.109Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia"}]},"_fixedFields":["pubmed(249)"],"trialDetails":[{"nctId":"NCT03983824","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-05-05","conditions":"Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":48},{"nctId":"NCT07490288","phase":"NA","title":"Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"AML","enrollment":30},{"nctId":"NCT07486479","phase":"PHASE3","title":"Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-03-10","conditions":"Acute Myeloid Leukemia (AML)","enrollment":204},{"nctId":"NCT03591510","phase":"PHASE2","title":"A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2019-03-13","conditions":"FLT3-mutated Acute Myeloid Leukemia","enrollment":22},{"nctId":"NCT06713837","phase":"PHASE3","title":"IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.","status":"RECRUITING","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2025-02-27","conditions":"Acute Myeloid Leukemia, Relapse/Recurrence","enrollment":339},{"nctId":"NCT04375631","phase":"PHASE1","title":"CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-12-03","conditions":"Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome","enrollment":120},{"nctId":"NCT04486391","phase":"PHASE3","title":"Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma","status":"TERMINATED","sponsor":"BeiGene","startDate":"2020-12-14","conditions":"Classical Hodgkin Lymphoma","enrollment":3},{"nctId":"NCT04293562","phase":"PHASE3","title":"A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2020-07-21","conditions":"Acute Myeloid Leukemia","enrollment":1186},{"nctId":"NCT02339740","phase":"PHASE3","title":"Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2015-07-21","conditions":"Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA","enrollment":158},{"nctId":"NCT03165851","phase":"","title":"Efficacy Analysis of Comparison of CAMS（Chinese Academy of Medical Sciences）-2005 Trial and CAMS-2009 Trial for Pediatric Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2005-04-10","conditions":"Acute Myeloid Leukemia, Pediatric","enrollment":320},{"nctId":"NCT02523976","phase":"PHASE2","title":"Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2015-08-01","conditions":"Acute,Leukemia, Lymphoid","enrollment":30},{"nctId":"NCT03182244","phase":"PHASE3","title":"A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma Inc","startDate":"2017-10-25","conditions":"AML With FLT3 Mutation","enrollment":276},{"nctId":"NCT06660368","phase":"PHASE2","title":"BCL2i CLAG-M in R/R Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-11-26","conditions":"Relapsed or Refractory Acute Myeloid Leukemia (AML)","enrollment":52},{"nctId":"NCT03164057","phase":"PHASE2","title":"A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-06-15","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":206},{"nctId":"NCT03926624","phase":"PHASE3","title":"Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage","status":"TERMINATED","sponsor":"Delta-Fly Pharma, Inc.","startDate":"2019-11-22","conditions":"Leukemia, Myeloid, Acute","enrollment":167},{"nctId":"NCT02553460","phase":"PHASE1, PHASE2","title":"Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2016-01-29","conditions":"Acute Lymphoblastic Leukemia","enrollment":50},{"nctId":"NCT05955261","phase":"PHASE2","title":"A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia","status":"SUSPENDED","sponsor":"St. Jude Children's Research Hospital","startDate":"2023-07-25","conditions":"Acute Myeloid Leukemia","enrollment":70},{"nctId":"NCT02421939","phase":"PHASE3","title":"A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2015-10-20","conditions":"Leukemia, Acute Myeloid (AML)","enrollment":371},{"nctId":"NCT02101853","phase":"PHASE3","title":"Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-12-17","conditions":"Recurrent B Acute Lymphoblastic Leukemia","enrollment":669},{"nctId":"NCT01371981","phase":"PHASE3","title":"Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-06-20","conditions":"Acute Myeloid Leukemia, Leukemia Cutis, Myeloid Neoplasm","enrollment":1645},{"nctId":"NCT06451861","phase":"PHASE2","title":"Randomized Study of ABC-14 Regimen Compared With \"3+7\" Standard Induction Therapy or AB-14 for ND AML","status":"RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2024-08-21","conditions":"Acute Myeloid Leukemia","enrollment":240},{"nctId":"NCT03118466","phase":"PHASE2","title":"Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2017-09-25","conditions":"AML","enrollment":41},{"nctId":"NCT04797767","phase":"PHASE1, PHASE2","title":"Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms","status":"RECRUITING","sponsor":"University of Washington","startDate":"2022-02-04","conditions":"Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia","enrollment":62},{"nctId":"NCT06621212","phase":"PHASE2","title":"Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-07-05","conditions":"Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy","enrollment":72},{"nctId":"NCT03860844","phase":"PHASE2","title":"Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Sanofi","startDate":"2019-08-06","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":67},{"nctId":"NCT06387069","phase":"PHASE3","title":"A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Hutchmed","startDate":"2024-04-26","conditions":"Acute Myeloid Leukemia","enrollment":316},{"nctId":"NCT07108530","phase":"PHASE2","title":"Efficacy of Integrated Induction-Consolidation Chemotherapy and Transplantation for Adult Acute Myeloid Leukemia: Multicenter Study","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-08-06","conditions":"Acute Myeloid Leukemia","enrollment":50},{"nctId":"NCT06265545","phase":"NA","title":"Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-02-22","conditions":"AML, Refractory, Relapsed","enrollment":120},{"nctId":"NCT06262438","phase":"PHASE2","title":"CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients","status":"RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2024-02-06","conditions":"Acute Myeloid Leukemia in Children","enrollment":60},{"nctId":"NCT02521493","phase":"PHASE3","title":"Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2015-12-23","conditions":"Acute Myeloid Leukemia, Down Syndrome, Myelodysplastic Syndrome","enrollment":280},{"nctId":"NCT06220097","phase":"PHASE2","title":"Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2022-02-01","conditions":"B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma Refractory","enrollment":28},{"nctId":"NCT04195945","phase":"PHASE2","title":"CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-03-11","conditions":"Acute Myeloid Leukemia, Myeloid Neoplasm","enrollment":60},{"nctId":"NCT05054543","phase":"PHASE3","title":"Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML","status":"TERMINATED","sponsor":"Apollomics Inc.","startDate":"2021-11-17","conditions":"Relapsed/Refractory AML","enrollment":140},{"nctId":"NCT04839341","phase":"PHASE1","title":"Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients","status":"COMPLETED","sponsor":"Apollomics Inc.","startDate":"2021-02-24","conditions":"Relapsed/Refractory AML","enrollment":12},{"nctId":"NCT02303821","phase":"PHASE1","title":"Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-02-16","conditions":"Acute Lymphoblastic Leukemia (ALL)","enrollment":141},{"nctId":"NCT05941585","phase":"NA","title":"Mitoxantrone Hydrochloride Liposome Combined With Chemotherapy in Untreated de Novo Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-08-08","conditions":"Acute Myeloid Leukemia","enrollment":60},{"nctId":"NCT01184898","phase":"NA","title":"Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2010-07","conditions":"AML","enrollment":36},{"nctId":"NCT00410423","phase":"PHASE1, PHASE2","title":"Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2006-01","conditions":"Relapsed Acute Leukemia, Refractory Acute Leukemia","enrollment":55},{"nctId":"NCT02632708","phase":"PHASE1","title":"Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut de Recherches Internationales Servier","startDate":"2015-12-31","conditions":"Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS)","enrollment":153},{"nctId":"NCT03150004","phase":"PHASE2","title":"Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients with Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)","status":"TERMINATED","sponsor":"Medical College of Wisconsin","startDate":"2017-06-14","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":53},{"nctId":"NCT04778410","phase":"PHASE2","title":"Study of Magrolimab Combinations in Participants With Myeloid Malignancies","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2021-06-28","conditions":"Myeloid Malignancies","enrollment":54},{"nctId":"NCT06757478","phase":"","title":"A Clinical Study on the Combination of Mitoxantrone Liposome Injection, Bendamustine, Etoposide, and Cytarabine for Pretreatment of Autologous Hematopoietic Stem Cell Transplantation in Patients with Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Ningbo University","startDate":"2025-05-01","conditions":"Lymphoma Patient","enrollment":30},{"nctId":"NCT02688140","phase":"PHASE3","title":"Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia","status":"COMPLETED","sponsor":"Technische Universität Dresden","startDate":"2016-06","conditions":"Acute Promyelocytic Leukemia","enrollment":135},{"nctId":"NCT06651866","phase":"PHASE1","title":"Dose-escalation Study of D-CMG Regimen for the Treatment of Elderly Newly Diagnosed AML Patients","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2024-12-12","conditions":"Acute Myeloid Leukemia","enrollment":18},{"nctId":"NCT05603884","phase":"PHASE2","title":"VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2022-12-01","conditions":"Leukemia, Myeloid, Acute, AML Stage, Adult","enrollment":66},{"nctId":"NCT06741722","phase":"PHASE2","title":"Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML","status":"RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2024-10-31","conditions":"AML, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT05904106","phase":"PHASE2","title":"Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML","status":"RECRUITING","sponsor":"Technische Universität Dresden","startDate":"2024-04-07","conditions":"Acute Myeloid Leukemia","enrollment":146},{"nctId":"NCT03441048","phase":"PHASE1","title":"Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2018-05-22","conditions":"Acute Myeloid Leukemia","enrollment":26},{"nctId":"NCT06621199","phase":"PHASE2","title":"Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AML","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-07-08","conditions":"Acute Myeloid Leukemia","enrollment":42},{"nctId":"NCT02484391","phase":"PHASE1","title":"CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2015-09","conditions":"Granulocytic Sarcoma, Recurrent Adult Acute Myeloid Leukemia","enrollment":48},{"nctId":"NCT02920008","phase":"PHASE3","title":"Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2017-03-16","conditions":"Acute Myeloid Leukemia","enrollment":302},{"nctId":"NCT02907359","phase":"PHASE3","title":"Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2017-01-13","conditions":"Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic","enrollment":417},{"nctId":"NCT06221683","phase":"PHASE2","title":"Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML","status":"RECRUITING","sponsor":"Children's Hospital of Soochow University","startDate":"2024-01-01","conditions":"AML, Childhood, Acute Myeloid Leukemia","enrollment":500},{"nctId":"NCT06007911","phase":"PHASE1","title":"Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia","status":"WITHDRAWN","sponsor":"Medical College of Wisconsin","startDate":"2024-08-31","conditions":"Relapsed Adult AML, Refractory AML","enrollment":""},{"nctId":"NCT03616470","phase":"PHASE3","title":"Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"GlycoMimetics Incorporated","startDate":"2018-10-15","conditions":"Acute Myeloid Leukemia","enrollment":388},{"nctId":"NCT06489808","phase":"PHASE2","title":"Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-05-28","conditions":"Relapsed/Refractory Large B-Cell Lymphoma","enrollment":89},{"nctId":"NCT02400281","phase":"PHASE1, PHASE2","title":"Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients","status":"COMPLETED","sponsor":"Arog Pharmaceuticals, Inc.","startDate":"2015-09","conditions":"Acute Myeloid Leukemia","enrollment":28},{"nctId":"NCT06447090","phase":"PHASE2","title":"VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCT","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-04-12","conditions":"Relapse Acute Myeloid Leukemia","enrollment":30},{"nctId":"NCT06434662","phase":"PHASE2","title":"Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AML","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-02-29","conditions":"Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy","enrollment":34},{"nctId":"NCT06345365","phase":"PHASE3","title":"MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)","status":"RECRUITING","sponsor":"Zhongnan Hospital","startDate":"2024-01-18","conditions":"Acute Myeloid Leukaemia","enrollment":154},{"nctId":"NCT06329999","phase":"NA","title":"A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-02-03","conditions":"Recurrent Adult Acute Myeloid Leukemia, Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia","enrollment":78},{"nctId":"NCT04330820","phase":"PHASE1, PHASE2","title":"Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)","status":"UNKNOWN","sponsor":"Technische Universität Dresden","startDate":"2020-04-06","conditions":"Relapsed Adult AML, Refractory AML","enrollment":55},{"nctId":"NCT01497002","phase":"PHASE3","title":"Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML>60a","status":"COMPLETED","sponsor":"University of Leipzig","startDate":"2005-04","conditions":"Acute Myeloid Leukaemia","enrollment":1222},{"nctId":"NCT02461537","phase":"PHASE3","title":"Impact of Remission Induction Chemotherapy Prior to Allogeneic SCT in Relapsed and Poor-response Patients With AML","status":"COMPLETED","sponsor":"DKMS gemeinnützige GmbH","startDate":"2015-09-17","conditions":"Acute Myeloid Leukemia","enrollment":281},{"nctId":"NCT06211452","phase":"PHASE3","title":"Comparison of Consolidation Strategies for Pediatric Patients With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Grupo Argentino de Tratamiento de la Leucemia Aguda","startDate":"2007-08-01","conditions":"AML, Pediatric AML","enrollment":258},{"nctId":"NCT04196010","phase":"PHASE1","title":"Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms","status":"TERMINATED","sponsor":"University of Washington","startDate":"2020-05-08","conditions":"Myeloid Neoplasm, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":13},{"nctId":"NCT02626338","phase":"PHASE1, PHASE2","title":"Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML","status":"COMPLETED","sponsor":"Arog Pharmaceuticals, Inc.","startDate":"2016-02","conditions":"Relapsed/Refractory Acute Myeloid Leukemia (AML)","enrollment":16},{"nctId":"NCT02520011","phase":"PHASE2","title":"Alvocidib Biomarker-driven Phase 2 AML Study","status":"TERMINATED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2016-03-14","conditions":"Acute Myeloid Leukemia","enrollment":104},{"nctId":"NCT02583893","phase":"PHASE2","title":"Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2015-10-07","conditions":"Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia","enrollment":39},{"nctId":"NCT03531918","phase":"PHASE1, PHASE2","title":"Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2018-09-14","conditions":"Acute Myeloid Leukemia","enrollment":66},{"nctId":"NCT05313958","phase":"PHASE2, PHASE3","title":"Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-12-01","conditions":"Leukemia, Monocytic, Acute, Pediatric AML","enrollment":43},{"nctId":"NCT02665065","phase":"PHASE3","title":"Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Actinium Pharmaceuticals","startDate":"2016-06","conditions":"Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute","enrollment":153},{"nctId":"NCT02728050","phase":"PHASE1, PHASE2","title":"Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"University of Washington","startDate":"2016-12-01","conditions":"Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, de Novo Myelodysplastic Syndrome","enrollment":84},{"nctId":"NCT02299518","phase":"PHASE1","title":"Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Alice Mims","startDate":"2015-05-18","conditions":"Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)","enrollment":23},{"nctId":"NCT05876832","phase":"PHASE3","title":"A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)","status":"NOT_YET_RECRUITING","sponsor":"Shijiazhuang Yiling Pharmaceutical Co. Ltd","startDate":"2023-06-15","conditions":"Acute Myeloid Leukemia With FLT3/ITD Mutation","enrollment":312},{"nctId":"NCT05330377","phase":"PHASE1","title":"GM-CLAG in Relapsed/Refractory FLT3-mutated AML","status":"WITHDRAWN","sponsor":"Ayman H Qasrawi","startDate":"2023-03","conditions":"Acute Myeloid Leukemia","enrollment":""},{"nctId":"NCT05814718","phase":"NA","title":"Modified BEAM Regimen for T Cell Lymphoma Underwent ASCT","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2023-04-15","conditions":"Autologous Stem Cell Transplantation, Conditioning","enrollment":122},{"nctId":"NCT05814731","phase":"NA","title":"Study on the Efficacy and Safety of MA-BUCY2 Conditioning in High-risk AML Patients Underwent Haplo-HSCT","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2023-04-15","conditions":"Haploidentical Stem Cell Transplantation, Conditioning","enrollment":264},{"nctId":"NCT00199069","phase":"PHASE4","title":"German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93)","status":"COMPLETED","sponsor":"Goethe University","startDate":"1993-04","conditions":"Adult Acute Lymphocytic Leukemia","enrollment":720},{"nctId":"NCT05739630","phase":"PHASE2, PHASE3","title":"M-PTCy vs BuCy in Haploidentical HSCT for Acute Leukemia","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-01-01","conditions":"Acute Leukemia","enrollment":60},{"nctId":"NCT03504410","phase":"PHASE3","title":"Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML","status":"TERMINATED","sponsor":"Cornerstone Pharmaceuticals","startDate":"2018-11-12","conditions":"Relapsed/Refractory Acute Myeloid Leukemia","enrollment":200},{"nctId":"NCT00003407","phase":"PHASE2","title":"Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML","status":"WITHDRAWN","sponsor":"Rush University Medical Center","startDate":"2001-02-13","conditions":"Drug/Agent Toxicity by Tissue/Organ, Leukemia, Myelodysplastic Syndromes","enrollment":""},{"nctId":"NCT05681403","phase":"NA","title":"Clinical Study of Improved BEAM Conditioning Regimen for ASCT in Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2023-01-15","conditions":"Lymphoma, Autologous Hematopoietic Stem Cell Transplantation","enrollment":53},{"nctId":"NCT01154439","phase":"PHASE1","title":"Everolimus MICE-regimen in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2010-10","conditions":"Leukemia","enrollment":11},{"nctId":"NCT01842672","phase":"PHASE1, PHASE2","title":"Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia","status":"COMPLETED","sponsor":"New York Medical College","startDate":"2013-03","conditions":"Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Lymphoblastic Lymphoma","enrollment":41},{"nctId":"NCT00866918","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2009-03-09","conditions":"Childhood Acute Promyelocytic Leukemia With PML-RARA, Myeloid Neoplasm","enrollment":106},{"nctId":"NCT02686593","phase":"PHASE2","title":"Clofarabine, Cytarabine and Mitoxantrone (CLAM) for Relapsed or Refractory AML","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2016-02-01","conditions":"Acute Myeloid Leukemia","enrollment":50},{"nctId":"NCT01700946","phase":"PHASE2","title":"Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-04-15","conditions":"Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood B-Lymphoblastic Lymphoma","enrollment":80},{"nctId":"NCT03989713","phase":"PHASE2","title":"Quizartinib and High-dose Ara-C Plus Mitoxantrone in Relapsed/Refractory AML With FLT3-ITD","status":"TERMINATED","sponsor":"Prof. Dr. Richard F Schlenk","startDate":"2020-07-17","conditions":"AML According to WHO 2016 Classification (Except Acute Promyelocytic Leukemia) AND (Refractory to Induction Therapy OR Relapsed After First Line Treatment)","enrollment":11},{"nctId":"NCT03173612","phase":"NA","title":"The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia","status":"UNKNOWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2016-08","conditions":"Acute Myeloid Leukemia","enrollment":132},{"nctId":"NCT01550185","phase":"PHASE1","title":"Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2012-05","conditions":"Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7)","enrollment":10},{"nctId":"NCT02551718","phase":"NA","title":"High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia","status":"COMPLETED","sponsor":"University of Washington","startDate":"2015-09-11","conditions":"Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia","enrollment":34},{"nctId":"NCT02200978","phase":"PHASE4","title":"A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia","status":"COMPLETED","sponsor":"South China Children's Leukemia Group","startDate":"2011-09","conditions":"Childhood Acute Promyelocytic Leukemia","enrollment":176},{"nctId":"NCT03563560","phase":"PHASE1","title":"A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Sumitomo Pharma Co., Ltd.","startDate":"2018-05-15","conditions":"Acute Myeloid Leukemia","enrollment":10},{"nctId":"NCT03012672","phase":"PHASE2","title":"Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm","status":"COMPLETED","sponsor":"University of Washington","startDate":"2016-12-30","conditions":"Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia, Myeloid Neoplasm","enrollment":50},{"nctId":"NCT05244642","phase":"PHASE3","title":"A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma","status":"RECRUITING","sponsor":"Akeso","startDate":"2022-02-15","conditions":"Hodgkin Disease Lymphoma","enrollment":60},{"nctId":"NCT02910752","phase":"PHASE1, PHASE2","title":"CLAM Chemotherapy With PBSC Support for Relapsed Patients After Allogeneic Stem Cell Transplantation","status":"SUSPENDED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2016-09","conditions":"Leukemia","enrollment":20},{"nctId":"NCT02756572","phase":"PHASE2","title":"Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms","status":"COMPLETED","sponsor":"University of Washington","startDate":"2016-09-22","conditions":"Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia-2, High Grade Malignant Neoplasm","enrollment":30},{"nctId":"NCT05100303","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Tolerance and Efficacy of Mitoxantrone Hydrochloride Liposome Injection Combined With Cytarabine in Patients With Acute Myeloid Leukemia (AML)","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2021-12","conditions":"Treatment-naive or Relapsed or Refractory Acute Myeloid Leukemia (AML)","enrollment":58},{"nctId":"NCT00003405","phase":"PHASE2","title":"Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia","status":"WITHDRAWN","sponsor":"Rush University Medical Center","startDate":"1998-04","conditions":"Leukemia","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":249,"recentPublications":[{"date":"2026","pmid":"41858364","title":"Case Report: Complete remission of refractory Langerhans cell sarcoma following CLAG-M chemotherapy and allogeneic hematopoietic stem cell transplant.","journal":"Frontiers in oncology"},{"date":"2026 Mar","pmid":"41791831","title":"Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1/2 trial.","journal":"The Lancet. Haematology"},{"date":"2025 Dec","pmid":"41607556","title":"A case report of histiocytic sarcoma mimicking acute pericarditis.","journal":"European heart journal. Case reports"},{"date":"2025 Aug","pmid":"40535475","title":"Phase 1 trial of venetoclax with cladribine, cytarabine, G-CSF, and mitoxantrone for AML and high-grade myeloid neoplasm.","journal":"Blood neoplasia"},{"date":"2025 Feb","pmid":"40051959","title":"Navigating Cytomegalovirus Retinitis in a Patient With Myelodysplastic Syndromes Transitioning to Acute Myeloid Leukemia Post Transplant: A Case Study.","journal":"Cureus"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"cytarabine and mitoxantrone","genericName":"cytarabine and mitoxantrone","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cytarabine is a nucleoside analog that interferes with DNA synthesis, while mitoxantrone is a topoisomerase II inhibitor that disrupts DNA replication and transcription. Used for Acute myeloid leukemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}